PRKCB and diffuse large B-cell lymphoma: As a key signaling hub downstream of BCR signaling, PKC-β has been an attractive target for treating DLBCL and the PKC-β inhibitor enzastaurin has been tested in refractory/relapsed or newly-diagnosed DLBCL patients.